Last reviewed · How we verify
Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes
The primary purpose of this study is to evaluate the efficacy of PAD-regimen and TAD-regimen in newly diagnosed multiple myeloma(MM).
Details
| Lead sponsor | Second Military Medical University |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 100 |
| Start date | 2010-06 |
| Completion | 2014-06 |
Conditions
- Multiple Myeloma
Interventions
- Bortezomib,Pirarubicin,Dexamethasone
- Thalidomide,Pirarubicin,Dexamethasone
Primary outcomes
- The overall response rate of PAD and TAD in patients with MM assessed by International Myeloma Working Group(IMWG) criteria — every treatment cycle
Countries
China